DREAM INT'L (01126) released its interim results, with profit attributable to shareholders of 206 million yuan, a year-on-year decrease of 32.95%.
Derlin International (01126) released its interim results for the six months ending June 30, 2026, reporting revenue of HK$2.896 billion, an increase of 12.34% year-on-year; the profit attributable to equity shareholders was HK$206 million, a decrease of 32.95% year-on-year; earnings per share were HK$0.304, and an interim dividend of HK$0.25 per share is proposed.
DREAM INT'L (01126) announced its interim results for the six months ending June 30, 2026. The group achieved revenue of HK$2.896 billion, an increase of 12.34% year-on-year; the profit attributable to equity shareholders was HK$206 million, a decrease of 32.95% year-on-year; and earnings per share were HK$0.304, with a proposed interim dividend of HK$0.25 per share.
As of June 30, 2026, the group operated a total of 31 factories, including nine in mainland China, 21 in Vietnam, and one in Indonesia, with an average utilization rate of 87.5%. The group continues to flexibly adjust the production capacity of its three main manufacturing bases to ensure timely delivery and agile response to shifts in order patterns. The group also continuously enhances production efficiency through automation, supply chain optimization, and rigorous production planning. Automated processes can increase productivity and reduce reliance on manual labor; meanwhile, strategies such as localized sourcing, open bidding, and forward purchasing of key raw materials help alleviate cost pressures and price fluctuations arising from geopolitical changes.
Related Articles

XINGFA ALUM (00098) announced its interim results, with a profit attributable to shareholders of 171 million yuan, a decrease of 36.97% compared to the same period last year.

XIKANG CLOUD (09686) released its interim results, reporting an adjusted net loss of 21.847 million yuan, a year-on-year decrease of 43.11%.

GRAND PHARMA (00512) reported a 55% year-on-year increase in revenue from its nuclear medicine business in the first half of the year, with collaborative innovation across multiple business segments sparking new vitality.
XINGFA ALUM (00098) announced its interim results, with a profit attributable to shareholders of 171 million yuan, a decrease of 36.97% compared to the same period last year.

XIKANG CLOUD (09686) released its interim results, reporting an adjusted net loss of 21.847 million yuan, a year-on-year decrease of 43.11%.

GRAND PHARMA (00512) reported a 55% year-on-year increase in revenue from its nuclear medicine business in the first half of the year, with collaborative innovation across multiple business segments sparking new vitality.

RECOMMEND





